key: cord-1054195-037vyj26 authors: Brix, Thomas H.; Hegedüs, Laszlo title: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and thyroid disease. An update date: 2021-07-06 journal: Curr Opin Endocrinol Diabetes Obes DOI: 10.1097/med.0000000000000654 sha: 4eb50bef2df4418283e91b5e4c2bbb3c484635b1 doc_id: 1054195 cord_uid: 037vyj26 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with excess morbidity and mortality in patients with hypertension and diabetes but little is known about thyroid diseases. Thus, our goal was to review the literature with respect to: (i) Are patients with underlying hypo- or hyperthyroidism at increased risk of contracting SARS-CoV-2 infection? (ii) do underlying hypo- and hyperthyroidism impact the prognosis of SARS-CoV-2 infection? (iii) does SARS-CoV-2 infection cause de novo thyroid dysfunction? RECENT FINDINGS: Patients with hypo- or hyperthyroidism do not have an increased risk of contracting SARS-CoV-2, and a diagnosis of hypo- or hyperthyroidism is not associated with a worsened prognosis of SARS-CoV-2 infection. SARS-CoV-2 infection has been associated with subsequent thyrotoxicosis, euthyroid sick syndrome, subacute thyroiditis, and autoimmune thyroid disease. SUMMARY: These findings suggest that receiving treatment for thyroid dysfunction does not per se impact the patients’ risk of acquiring SARS-CoV-2 infection, or the management of those who already contracted it. Additional studies with larger numbers of patients and long-term follow-up are required in order to clarify whether patients with SARS-CoV-2 infection are more or less prone to develop thyroid dysfunction and/or thyroid autoimmunity than patients recovering from other virus infections. Coronavirus disease 2019 (COVID- 19) , which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection [1] has spread dramatically worldwide and is associated with excess morbidity and mortality. By end of April 2021, the virus had affected more than 140 million people and claimed more than 3 million lives. Identification of factors contributing to the risk of contracting SARS-CoV-2, and the subsequent prognosis in those affected, is important in order to optimize the reallocation of hospital resources, and guide public health recommendations and interventions. Hospital-based case series [2] [3] [4] as well as population-based cohort studies [5, 6] have found old age, male gender, and presence of a wide range of comorbidities, especially hypertension and diabetes, the main risk factors for severe disease and death. Whether underlying hypoor hyperthyroidism influence the risk and/or course of SARS-CoV-2 infection is less clear. Both the American Thyroid Association [https://www.thyroid.org/ covid-19/statement-covid-19] and the European Thyroid Association [https://www.eurothyroid. com/files/download/ETA-PHB.pdf] have issued consensus statements to patients receiving treatment for thyroid dysfunction. Although these recommendations were not anchored in strong clinical evidencebased data, they advise patients to continue their prescribed medications of Levothyroxine (L-T4) and antithyroid drugs (ATD) for hypo-and Theoretically, patients with hypo-or hyperthyroidism may have an increased risk of contracting and/ or developing a severe course of COVID-19. First, as SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry [8] , thyroid dysfunction may influence the risk and course of COVID-19 because the activity of ACE2 is influenced by serum levels of thyroid hormones [9, 10] . Second, patients with hypo-or hyperthyroidism have an increased burden of somatic [11, 12] , especially cardiovascular [13, 14] , and psychiatric [15, 16] co-morbidity, which is also reported in patients with severe and fatal COVID-19 [2, 3, 5, 6] . Third, in most patients the etiology of hypo-and hyperthyroidism is of autoimmune origin (95% and 50% for hypo-and hyperthyroidism, respectively) [17, 18] . Although patients with autoimmune disorders do not appear to be more likely to contract COVID-19 [19, 20 && ], they may have severe complications if their immune system is suppressed by their medication [19, 21] , e.g., risk of agranulocytosis in patients treated with ATD [22] . It remains debated whether the aforementioned conditions translate into increased risk of acquiring or a more severe prognosis of SARS-CoV-2 infection in patients with hypo-or hyperthyroidism. During the first 6 months of the COVID-19 pandemic, there was virtually no data on the risk of COVID-19 in patients with underlying thyroid dysfunction. By the second half of 2020, large-scale population-based epidemiological data have quantified the risk of contracting SARS-CoV-2 infection among patients diagnosed with Graves' disease (GD) [20 && ] and in patients treated for hypo-or hyperthyroidism [23 & ]. Table 1 outlines the results of these studies. In order to investigate the prevalence of SARS-CoV-2 infection in patients with various autoimmune diseases, Attauabi et al. [20 && ] analyzed, all individuals tested for SARS-CoV-2 between January 28 and June 2, 2020 in two Danish regions (Capital and Zealand). During the study period, 14 A worsened outcome of SARS-CoV-2 infection is demonstrated in individuals with morbidities such as hypertension and diabetes, but less is known about thyroid disorders. Evidence from recent studies suggests that receiving treatment for thyroid dysfunction does not per se impact the patients' risk of acquiring SARS-CoV-2 infection. These studies also show that a diagnosis of preexisting thyroid dysfunction, after adjustment for relevant confounding, does not influence the prognosis of SARS-CoV-2 infection. Additional studies are required to clarify whether patients with SARS-CoV-2 infection have a different propensity for developing thyroid dysfunction and/or thyroid autoimmunity than patients recovering from other virus infections. Findings from a meta-analysis of eight retrospective hospital-based observational studies have suggested that patients with thyroid disease are at increased risk of worsened outcomes of SARS-CoV-2 infection [27] . However, six studies included < 10 patients with a thyroid condition [28] [29] [30] [31] [32] [33] , three studies did not differentiate between hypo-and hyperthyroid individuals [32] [33] [34] , and one study did not include patients with SARS-CoV-2 infection [29] , hampering any guidance of patients and physicians. Subsequently, two controlled studies have evaluated the course of SARS-CoV-2 infection in patients with various thyroid conditions, such as hypothyroidism [35 & ], and patients treated for either hypoor hyperthyroidism [23 & ]. Table 2 summarizes the findings of these studies. Using data from the New ] ascertained 572 (3.5%) and 75 (0.5%) SARS-CoV-2 positive patients who were current users of L-T4 and ATD, respectively. In order to evaluate the prognosis, patients with and without use of L-T4/ATD were followed prospectively until 30 days after their positive SARS-CoV-2 test. To minimize bias and confounding the analyses were adjusted for age, sex and various comorbidities using propensity score weighting. Compared with nonusers, current users of L-T4 had an increased risk of being hospitalized . However, when extending the follow-up to 60 days and taking different test strategies into account these associations attenuated, and the authors concluded that current use of L-T4 did not impact the prognosis of the SARS-CoV-2 infected. Likewise, current use of ATD was not associated with adverse outcomes of SARS-CoV-2 infection ( Table 2 ). Large-scale controlled studies show that patients with underlying thyroid dysfunction are no more prone to SARS-CoV-2 infection than the background population. These studies also suggest that preexisting thyroid dysfunction, when controlling for relevant confounding, does not influence the prognosis of SARS-CoV-2 infection. Although the data quality in these studies [20 && & ] is high, the results robust and pointing in the same direction, some limitations deserve attention. First, as patients with hypo-and hyperthyroidism, irrespective of cause, have an increased burden of SARS-CoV-2 related co-morbidities [11, 12] , many will be classified as vulnerable or high-risk patients and be advised to exhibit cautious behavior to limit risk of becoming infected. Thus, it cannot be ruled out that patients with underlying thyroid dysfunction may have been more observant than persons without thyroid disease, and as a consequence have limited their risk of contracting SARS-CoV-2 infection. Second, in the study by Attauabi et al. [20 && ] GD patients were identified based on a record in The Danish National Patient Registry. This registry only covers patients diagnosed in the secondary healthcare system, questioning the generalizability of these findings to other ascertainment situations and populations. Moreover, the authors offer no information on the timeframe between the diagnosis of GD and the SARS-CoV-2 test, rendering it impossible to evaluate whether the patients had active disease or were in remission on the date of the SARS-CoV-2 test. Third, all patients in the study by Brix et al. Theoretically, SARS-CoV-2 infection could lead to subsequent thyroid dysfunction. First, viral infections, including influenza [36] , human immunodeficiency virus [37] , and other coronaviruses such as SARS-CoV [38] , have been cited as environmental factors involved in subacute thyroiditis and autoimmune thyroid diseases [39] [40] [41] . Second, alterations in thyroid function tests, especially low triiodothyronine (T3) also known as Nonthyroidal illness syndrome (NTI), occur in many with a significant acute disease [42] . Third, ACE2 is present in the thyroid gland [43, 44] , making the thyroid susceptible to tissue injury as observed in other organs such as the lungs, gastrointestinal duct, and myocardium, which also harbor high levels of ACE2 [43] . Thyrotoxicosis, hypothyroidism, and low serum TSH have been reported in up to 20%, 5%, and 39%, respectively, in patients hospitalized with SARS-CoV-2 infection [46, 49, 52] . However, these studies did not include a control population, hampering interpreting the SARS-CoV-2-specific pattern and potential clinical relevance of these findings. Three studies (summarized in ]. In the retrospective study by Chen et al. [45 & ], thyroid function parameters in 50 hospitalized patients with SARS-CoV-2 were compared with those of a healthy control group matched for age and sex, and a group of non-COVID-19 pneumonia patients. At admission (defined as within 3 days), 56% (28/50) of hospitalized SARS-CoV-2 positive patients without previous thyroid diseases, showed lower-than-normal values for TSH (<0.3 mIU/L). Although, actual numbers for the two control groups are not given, this finding was reported significant when compared with the healthy control group. Unfortunately, the authors do not report comparison of the frequency of low TSH between SARS-CoV-2 cases and the non-COVID-19 pneumonia patients. The SARS-CoV-2 infected had significantly lower levels of TSH and total T3 as compared both with the healthy subjects and those with non-COVID-19 pneumonia. Total T4 levels did not differ between the three groups ( ] investigated thyroid function variables in 85 consecutive SARS-CoV-2 patients admitted to an intensive care unit (ICU) from 3 March to 28 April 2020. Patients treated in the same unit during the equivalent timeframe in 2019 served as controls. Thyroid function was assessed within 2 days of hospital admittance and a significantly higher prevalence of thyrotoxicosis (15%), low (25%), or suppressed TSH (9%), compared to 1%, 8%, and 1%, respectively, in the control group was reported. There was no difference in the prevalence of hypothyroidism between the two groups ( Table 3) . Levels of TSH were significantly lower in SARS-CoV-2 patients than in controls, whereas free T3 and free T4 were similar, and interpreted as a combination of thyrotoxicosis, due to ], comparing thyroid function variables (within 2 days after hospital admission) between 334 patients with SARS-CoV-2 infection and 122 patients with a clinical suspicion of COVID-19 but with a negative test. The prevalence of thyroid dysfunction was similar between patients with and without SARS-CoV-2 infection ( Table 3) . Levels of TSH and free T4 were significantly lower among patients with SARS-CoV-2 as compared to patients testing negative, despite having clinical symptoms. The authors concluded that there was no evidence for a SARS-CoV-2 related thyroiditis/thyrotoxicosis, and their findings most likely explained by NTI. [53] [54] [55] , postpartum thyroiditis [56] , and GD [57] [58] [59] following SARS-CoV-2 infection. Accepting the dogma that subacute thyroiditis and autoimmune thyroid diseases are related to prior viral infection [39, 41] , this is not surprising. However, lacking large-scale studies investigating the thyroid consequences following SARS-CoV-2 infection makes it impossible to evaluate whether these patients are more or less prone to develop thyroid dysfunction and/or thyroid autoimmunity than patients recovering from other virus infections. Patients with hypo-or hyperthyroidism do not have an increased risk of contracting SARS-CoV-2, and when adjusted for comorbidity, a diagnosis of hypoor hyperthyroidism is not associated with a worsened prognosis of SARS-CoV-2 infection. The clinical implications of and recommendations following these findings are that receiving treatment for thyroid dysfunction should not per se impact the patients' risk of acquiring SARS-CoV-2 infection, or the management of those who already contracted it. Although this information is based on robust data, a number of issues remain to be clarified. Thus, whether etiology of the thyroid dysfunction [60] , magnitude of thyroid dysfunction before/during infection, and cumulative period of thyroid dysfunction before infection, which clearly influence mortality [61, 62] also influence the risk and prognosis of SARS-CoV-2 infection are unknown. In patients hospitalized due to SARS-CoV-2 infection, alterations in thyroid function parameters reflecting thyrotoxicosis and NTI have been observed. Development of subacute thyroiditis and autoimmune thyroid disease following SARS-CoV-2 infection have also been reported, but additional studies with larger numbers of patients and long-term follow-up are needed to substantiate these observations. Characteristics of SARS-CoV-2 and COVID Clinical characteristics of coronavirus disease 2019 in China. The Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study Global epidemiology of hyperthyroidism and hypothyroidism SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy Coronaviruses and integrin avb3: does thyroid hormone modify the relationship? Type and extent of somatic morbidity before and after the diagnosis of hypothyroidism. a nationwide register study Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study Duration of overand under-treatment of hypothyroidism is associated with increased cardiovascular risk Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide register study Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study Epidemiology of subtypes of hypothyroidism in Denmark Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study SARS-CoV-2 infection among patients with systemic autoimmune diseases Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease-A Danish Prospective Population-based Cohort Study By utelizing nonbiased data from a number of Danish health databases, this large scale population based study provide valid estimates for risk and prognosis of SARS-CoV-2 infection in patients with inflammatory bowel disease and various other autoimmune diseases, including Graves' disease. Their results have important impact in guiding health recommendations and interventions in patients COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism By utilizing nonbiased data from a number of Danish health databases, this nationwide population based study provide valid estimates for risk and prognosis of SARS-CoV-2 infection in patients receiving treatment for underlying hypo-and hyperthyroidism. In this study, patients treated for hypo-or hyperthyroidism did not have an increased risk of contracting SARS-CoV-2, and treatment for hypo-or hyperthyroidism is not associated with a worse prognosis of SARS-CoV-2 infection. These results have important impact in guiding health recommendations and interventions in patients receiving treatment for Existing data sources in clinical epidemiology: The Danish COVID-19 Cohort Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection Clinical features of patients infected with the 2019 novel coronavirus (COVID-19 Low T3 syndrome is a strong predictor of poor outcomes in patients with community-acquired pneumonia Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at Hospital Admission in Shenzhen Clinical characteristics of coronavirus disease Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China Prognostic factors in Spanish COVID-19 patients: a case series from Barcelona Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study After adjusting for age, sex, race, BMI, smoking status and relevant comorbidities, the risk of hospitalization, use of mechanical ventilation, and death did not differ between patients with and without a diagnosis of hypothyroidism Subacute thyroiditis in the course of novel H1N1 influenza infection A case of subacute thyroiditis associated with primary HIV infection Pathology of the thyroid in severe acute respiratory syndrome Viruses and thyroiditis: an update Thyroid complications of SARS and coronavirus disease 2019 (COVID-19) Heged€ us L. The transition of subacute thyroiditis to Graves' disease as evidenced by diagnostic imaging Nonthyroidal illness in the ICU: a syndrome with different faces Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis Thyroid function analysis in 50 patients with COVID-19: a retrospective study In this retrospective study serum levels of thyroid function parameters in 50 hospitalized patients with SARS-CoV-2 were compared with those of a healthy control group matched for age and sex, and a group of non-COVID-19 pneumonia patients. At admission, 56% (28/50) of hospitalized SARS-CoV-2 positive patients without previous thyroid diseases, showed lower-thannormal values for TSH (<0.3 mIU/L). Patients with SARS-CoV-2 infection had significantly lower serum levels of TSH and total triiodothyronine (T3) as compared both with the healthy subjects and with patients with non-COVID-19 pneumonia Thyrotoxicosis in patients with COVID-19: the THYRCOV study SARS-CoV-2-related atypical thyroiditis The study examined thyroid function variables in 85 consecutive SARS-CoV-2 patients admitted to an intensive care unit. Patients treated in the same unit during the equivalent time frame in 2019 served as controls. Serum levels of TSH were significantly lower in SARS-CoV-2 patients than in controls, while the levels of free T3 and free T4 were similar, suggesting a combination of thyrotoxicosis due to atypical thyroiditis and nonthyroideal ilness in SARS-CoV-2 patients Thyroid function before, during, and after COVID-19 This study compare thyroid function variables between 334 patients hospitalized due to with SARS-CoV-2 infection and 122 patients hospitalized due to a clinical suspicion of COVID-19 but with a negative SARS-CoV-2 test. Ad admission, the prevalence of thyroid dysfunction was similar between patients with and without SARS-CoV-2 infection. During the hospital stay, serum levels of TSH and free T4 were significantly lower among patients with SARS-CoV-2 Thyroid dysfunction in relation to immune profile, disease status and outcome in 191 patients with COVID-19 Thyroid hormone concentrations in severely or critically ill patients with COVID-19 Euthyroid sick syndrome in patients with COVID-19 The spectrum of thyroid function tests during hospitalization for SARS-COV-2 infection Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series Subacute thyroiditis associated with COVID-19 A case of postpartum thyroiditis following SARS-CoV-2 infection Graves' thyrotoxicosis following SARS-CoV-2 infection COVID-19: a cause of recurrent Graves' hyperthyroidism? SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19 Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH Over-and undertreatment of hypothyroidism is associated with excess mortality: a registerbased cohort study Financial support and sponsorship None.